Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR3680 plus ADT versus bicalutamide plus ADT in high-volume metastatic hormone-sensitive prostate cancer
2018-003190-96Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing SHR3680 + ADT with Bicalutamide + ADT (2 arms). Primary endpoints: radiographic progression-free survival and overall survival. Started Apr 2019; status: active.
02
Drugs
rezvilutamidebicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2018-003190-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003190-96.